Back to top
more

Avidity Biosciences (RNA)

(Real Time Quote from BATS)

$37.95 USD

37.95
1,430,185

+2.03 (5.65%)

Updated Aug 4, 2025 02:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avidity Biosciences (RNA) delivered earnings and revenue surprises of -2.27% and 46.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 4.76% and 29.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

by Zacks Equity Research

NVAX and RNA are in the spotlight following Q3 results and study data, respectively.

Zacks Equity Research

RNA Stock Hits Record High on Entering the Cardiac Disease Space

by Zacks Equity Research

Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 17.72% and 67.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of 17.86% and 249.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Company News for Aug 13, 2024

by Zacks Equity Research

Companies in The News Are: GOLD,MNDY,IBRX,RNA

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 14.47% and 71.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -9.30% and 70.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

by Zacks Equity Research

Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -46.30% and 93.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?

by Zacks Equity Research

Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

by Zacks Equity Research

Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Zacks Equity Research

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

by Zacks Equity Research

Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.

Zacks Equity Research

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

by Zacks Equity Research

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

by Zacks Equity Research

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Zacks Equity Research

Company News for Nov 29, 2023

by Zacks Equity Research

Companies in The News Are: ESLT,RNA,ZS,SDRL

Zacks Equity Research

Avidity (RNA) Expands Collaboration With BMY, Shares Rise

by Zacks Equity Research

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 21.43% and 11.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?